Research programme: STAT3 transcription factor inhibitors - Moleculin Biotech

Drug Profile

Research programme: STAT3 transcription factor inhibitors - Moleculin Biotech

Alternative Names: CABE; caffeic acid benzyl ester; caffeic acid phenyl ester; CAPE

Latest Information Update: 29 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Moleculin; University of Texas M. D. Anderson Cancer Center
  • Developer Moleculin Biotech
  • Class Caffeic acids; Cinnamates
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Psoriasis
  • Research Cancer

Most Recent Events

  • 15 Oct 2013 Development for Cancer and Psoriasis is ongoing in USA
  • 10 Nov 2010 Early research in Cancer in USA (Topical)
  • 10 Nov 2010 Preclinical trials in Psoriasis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top